Login to Your Account

Tolero Licenses Btk Drugs from MannKind for $130M

By Catherine Shaffer
Staff Writer

Tuesday, May 1, 2012

A new license agreement between Tolero Pharmaceuticals Inc., of Salt Lake City, and MannKind Corp., of Valencia, Calif., will grant Tolero exclusive worldwide rights to some of MannKind's Bruton's tyrosine kinase (Btk) compounds, which have potential for hematological malignancies and inflammatory disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription